Your browser doesn't support javascript.
ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 Working Group.
Goel, Ruchika; Bloch, Evan M; Pirenne, France; Al-Riyami, Arwa Z; Crowe, Elizabeth; Dau, Laetitia; Land, Kevin; Townsend, Mary; Jecko, Thachil; Rahimi-Levene, Naomi; Patidar, Gopal; Josephson, Cassandra D; Arora, Satyam; Vermeulen, Marion; Vrielink, Hans; Montemayor, Celina; Oreh, Adaeze; Hindawi, Salwa; van den Berg, Karin; Serrano, Katherine; So-Osman, Cynthia; Wood, Erica; Devine, Dana V; Spitalnik, Steven L.
  • Goel R; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Bloch EM; Division of Hematology/Oncology, Simmons Cancer Institute at SIU School of Medicine and Mississippi Valley Regional Blood Center, Springfield, IL, USA.
  • Pirenne F; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Al-Riyami AZ; Etablissement Français du Sang Ile de France, Hôpital Henri Mondor, Créteil, France.
  • Crowe E; Department of Hematology, Sultan Qaboos University Hospital, Muscat, Sultanate of Oman.
  • Dau L; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Land K; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  • Townsend M; Vitalant, Scottsdale, AZ, USA.
  • Jecko T; Department of Pathology, UT, San Antonio, TX, USA.
  • Rahimi-Levene N; Vitalant, Scottsdale, AZ, USA.
  • Patidar G; Manchester University NHS, Manchester, UK.
  • Josephson CD; Shamir Medical Center, Be'er Ya'akov, Israel.
  • Arora S; Department of Transfusion Medicine, All India Institute of Medical Sciences, New Delhi, India.
  • Vermeulen M; Department of Pathology, Emory University, Atlanta, GA, USA.
  • Vrielink H; Super Speciality Pediatric Hospital and Post Graduate Teaching Institute, Noida, India.
  • Montemayor C; The South African National Blood Service, Port Elizabeth, South Africa.
  • Oreh A; Dept Unit Transfusion Medicine, Sanquin Bloodbank, Amsterdam, the Netherlands.
  • Hindawi S; Canadian Blood Services, Ottawa, ON, Canada.
  • van den Berg K; National Blood Transfusion Service, Department of Hospital Services, Federal Ministry of Health, Abuja, Nigeria.
  • Serrano K; King Abdalaziz University, Jeddah, Saudi Arabia.
  • So-Osman C; Translational Research Department, Medical Division, South African National Blood Service, Port Elizabeth, South Africa.
  • Wood E; Division of Clinical Haematology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
  • Devine DV; Canadian Blood Services, Vancouver, BC, Canada.
  • Spitalnik SL; Department of Pathology & Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
Vox Sang ; 116(8): 849-861, 2021 Sep.
Article in English | MEDLINE | ID: covidwho-1402984
ABSTRACT
Growing evidence suggests that ABO blood group may play a role in the immunopathogenesis of SARS-CoV-2 infection, with group O individuals less likely to test positive and group A conferring a higher susceptibility to infection and propensity to severe disease. The level of evidence supporting an association between ABO type and SARS-CoV-2/COVID-19 ranges from small observational studies, to genome-wide-association-analyses and country-level meta-regression analyses. ABO blood group antigens are oligosaccharides expressed on red cells and other tissues (notably endothelium). There are several hypotheses to explain the differences in SARS-CoV-2 infection by ABO type. For example, anti-A and/or anti-B antibodies (e.g. present in group O individuals) could bind to corresponding antigens on the viral envelope and contribute to viral neutralization, thereby preventing target cell infection. The SARS-CoV-2 virus and SARS-CoV spike (S) proteins may be bound by anti-A isoagglutinins (e.g. present in group O and group B individuals), which may block interactions between virus and angiotensin-converting-enzyme-2-receptor, thereby preventing entry into lung epithelial cells. ABO type-associated variations in angiotensin-converting enzyme-1 activity and levels of von Willebrand factor (VWF) and factor VIII could also influence adverse outcomes, notably in group A individuals who express high VWF levels. In conclusion, group O may be associated with a lower risk of SARS-CoV-2 infection and group A may be associated with a higher risk of SARS-CoV-2 infection along with severe disease. However, prospective and mechanistic studies are needed to verify several of the proposed associations. Based on the strength of available studies, there are insufficient data for guiding policy in this regard.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: ABO Blood-Group System / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: Vox Sang Year: 2021 Document Type: Article Affiliation country: Vox.13076

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: ABO Blood-Group System / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials / Reviews Limits: Humans Language: English Journal: Vox Sang Year: 2021 Document Type: Article Affiliation country: Vox.13076